Table 1.
Patient characteristics and CVD risk factors among cancer survivors who completed and did not complete CR (N = 442).
| Variable (baseline values) | Total sample (N = 442) | CR completer (N = 361) | CR non-completers (N = 81) | t-Test/Chi-square test p-Value |
|---|---|---|---|---|
| Male sex | 344 (77.80) | 288 (80.00) | 56 (69.00) | 0.037 |
| Age (Years; group means/SD) | 67.36 (9.53) | 67.73 (9.12) | 65.73 (11.13) | 0.088 |
| Age (categories) N (%) | 0.082 | |||
| 30–39.9 years | 3 (0.7) | 1 (0.3) | 2 (2.5) | |
| 40–49.9 years | 17 (3.8) | 12 (3.3) | 5 (6.2) | |
| 50–59.9 years | 80 (18.1) | 65 (18.0) | 15 (18.5) | |
| 60–69.9 years | 153 (34.6) | 123 (34.1) | 30 (37.0) | |
| 70–79.9 years | 157 (35.5) | 136 (37.7) | 21 (25.0) | |
| ≥80 years | 32 (7.2) | 24 (6.6) | 8 (9.9) | |
| Smoking status | ||||
| Former smoker | 192 (43.4) | 158 (43.8) | 34 (42.0) | 0.769 |
| Current smoker | 67 (15.2) | 51 (14.1) | 16 (19.7) | 0.202 |
| Never smoked | 183 (41.4) | 152 (42.1) | 31 (38.3) | |
| Waist circumference (cm) | 102.04 (13.75) | 101.74 (13.75) | 103.47 (13.76) | 0.415 |
| Mean body mass index (kg/m2) | 28.09 (4.90) | 27.99 (4.67) | 28.57 (5.80) | 0.345 |
| BMI by category; N (%) | 0.036 | |||
| < 18.5 | 2 (0.50) | 0 | 2 (2.5) | |
| 18.5–24.99 | 108 (24.4) | 93 (25.8) | 15 (18.5) | |
| 25.0–29.99 | 188 (42.5) | 154 (42.7) | 34 (42) | |
| 30.0–34.99 | 91 (20.6) | 73 (20.2) | 18 (22.2) | |
| 35.0–39.99 | 25 (5.7) | 20 (5.5) | 5 (6.2) | |
| ≥40.00 | 9 (2.0) | 6 (1.7) | 3 (3.7) | |
| Attended home CR program | 85 (19.2) | 65 (18) | 20 (25) | 0.168 |
| HDL(mmol/L) | 1.21 (1.15) | 1.20 (0.37) | 1.22 (0.45) | 0.714 |
| LDL (mm/L) | 1.98 (0.86) | 1.98 (0.88) | 1.99 (0.78) | 0.892 |
| Total cholesterol (mmol/L) | 3.84 (1.02) | 3.81 (1.01) | 3.99 (0.94) | 0.277 |
| Triglycerides (mmol/L) | 1.49 (0.90) | 1.45 (0.89) | 1.70 (0.92) | 0.053 |
| Resting SBP (mmHg; N = 414) | 119.74 (19.51) | 120.43 (19.64) | 116.26 (18.58) | 0.105 |
| Resting DBP (mmHg; N = 416) | 71.59 (10.06) | 71.63 (10.14) | 71.35 (9.74) | 0.830 |
| Comorbidities | ||||
| Type II Diabetes | 100 (22.6) | 71 (20) | 25 (31) | 0.027 |
| Hypertension | 284 (64.3) | 230 (64) | 54 (67) | 0.616 |
| CHF | 45 (10.2) | 32 (9) | 13 (16) | 0.053 |
| COPD | 98 (22.2) | 73 (20) | 25 (31) | 0.037 |
| Liver/GI disease | 63 (14.3) | 52 (14) | 11 (14) | 0.848 |
| Renal disease | 17 (3.8) | 12 (3) | 5 (6) | 0.228 |
| PVD | 21 (4.8) | 17 (5) | 4 (5) | 0.930 |
| Cardiac history | ||||
| Prior CABG | 47 (10.6) | 35 (10) | 12 (15) | 0.177 |
| Prior PCI | 47 (10.6) | 34 (9) | 13 (16) | 0.080 |
| Prior MI | 85 (19.2) | 66 (18) | 19 (23) | 0.286 |
| aDuke Jeopardy Score (time of catheterization) | 0.426 | |||
| 0 | 51 | 13 | ||
| 2 | 109 | 28 | ||
| 4 | 46 | 10 | ||
| 6 | 70 | 10 | ||
| aDuke Jeopardy Score (time of catheterization) | ||||
| 8 | 22 | 7 | ||
| 10 | 21 | 1 | ||
| 12 | 32 | 8 |
Note. BMI = body mass index, CABG = coronary artery bypass graft, CHF = coronary heart failure, COPD = chronic obstructive pulmonary disease, CR = cardiac rehabilitation, CVD = cardiovascular disease, HDL = high density lipoprotein, GI = gastrointestinal, LDL = low density lipoprotein, MI = myocardial infarction, PCI = percutaneous coronary intervention, PVD = peripheral vascular disease, STEMI = ST elevation myocardial infarction.
Missing: Waist circumference, n = 148; BMI, n = 19; LDL, n = 84; HDL, n = 78; Total Cholesterol, n = 79; Triglycerides, n = 79; Resting SBP, n = 28; Resting DBP, n = 26.
Bold print indicates statistical significance; p<0.05.
The Duke Jeopardy score estimates myocardium risk according to location of coronary artery stenoses. Greater Jeopardy Scores are associated with lower left ventricular ejection fraction post-MI and decreased five-year survival in patients with CAD [15].